内科理论与实践››2022,Vol. 17››Issue (03): 181-185.doi:10.16138/j.1673-6087.2022.03.001
• 专家论坛 •下一篇
赵东宝
收稿日期:2022-01-05出版日期:2022-05-30发布日期:2022-08-09
Received:2022-01-05Online:2022-05-30Published:2022-08-09| [1] | George S, Aline B. Osteoimmunology[M]//Marc CH, Alan JS, Josef SS, et al. Rheumatology. 6th ed. Philadelphia, USA: Elsevier Mosby, 2015: 165-168. |
| [2] | Horton JE, Raisz LG, Simmons HA, et al. Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes[J]. Science, 1972, 177(4051): 793795. |
| [3] | Mundy GR, Luben RA, Raisz LG, et al. Bone-resorbing activity in supernatants from lymphoid cell lines[J]. New Engl J Med, 1974, 290(16): 867-871. pmid:4816960 |
| [4] | Srivastava RK, Dar HY, Mishra PK. Immunoporosis: immunology of osteoporosis-role of T cells[J]. Front Immunol, 2018, 9: 657. doi:10.3389/fimmu.2018.00657pmid:29675022 |
| [5] | Ke K, Sul OJ, Chung SW, et al. Lack of NOD2 attenuates ovariectomy-induced bone loss via inhibition of osteoclasts[J]. J Endocrinol, 2017, 235(2): 85-96. doi:10.1530/JOE-16-0591pmid:28778866 |
| [6] | Souza PPC, Lerner UH. Finding a Toll on the route: the fate of osteoclast progenitors after Toll-like receptor activation[J]. Front Immunol, 2019, 10: 1663. doi:10.3389/fimmu.2019.01663URL |
| [7] | Plotkin LI, Essex AL, Davis HM. RAGE signaling in skeletal biology[J]. Curr Osteoporos Rep, 2019, 17(1): 16-25. doi:10.1007/s11914-019-00499-wpmid:30685821 |
| [8] | Karner CM, Long F. Glucose metabolism in bone[J]. Bone, 2018, 115: 2-7. doi:10.1016/j.bone.2017.08.008URL |
| [9] | Chang MK, Raggatt LJ, Alexander KA, et al. Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast functionin vitroandin vivo[J]. J Immunol, 2008, 181(2):1232-1244. pmid:18606677 |
| [10] | Huang R, Wang X, Zhou Y, et al. RANKL-induced M1 macrophages are involved in bone formation[J]. Bone Res, 2017, 5: 17019. doi:10.1038/boneres.2017.19pmid:29263936 |
| [11] | Dou C, Ding N, Zhao C, et al. Estrogen deficiency-mediated M2 macrophage osteoclastogenesis contributes to M1/M2 ratio alteration in ovariectomized osteoporotic mice[J]. J Bone Miner Res, 2018, 33(5): 899-908. doi:10.1002/jbmr.3364pmid:29281118 |
| [12] | Omata Y, Frech M, Primbs T, et al. Group 2 innate lymphoid cells attenuate inflammatory arthritis and protect from bone destruction in mice[J]. Cell Rep, 2018, 24(1):169-180. doi:10.1016/j.celrep.2018.06.005URL |
| [13] | Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand[J]. Nature, 1999, 402(6759): 304-309. doi:10.1038/46303URL |
| [14] | Pugliese LS, Gonçalves TO, Popi AF, et al. B-1 lymphocytes differentiate into functional osteoclast-like cells[J]. Immunobiology, 2012, 217(3): 336-344. doi:10.1016/j.imbio.2011.07.014pmid:21855167 |
| [15] | Fujiwara Y, Piemontese M, Liu Y, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients[J]. J Biol Chem, 2016, 291: 24838-24850. pmid:27733688 |
| [16] | Adami G, Fassio A, Rossini M, et al. Osteoporosis in rheumatic diseases[J]. Int J Mol Sci, 2019, 20(23): 5867. doi:10.3390/ijms20235867URL |
| [17] | Orsolini G, Caimmi C, Viapiana O, et al. Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients[J]. Calcif Tissue Int, 2017, 101(1): 17-23. doi:10.1007/s00223-017-0253-8URL |
| [18] | van der Weijden MA, Claushuis TA, Nazari T, et al. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review[J]. Clin Rheumatol, 2012, 31(11): 1529-1535. doi:10.1007/s10067-012-2018-0pmid:22706444 |
| [19] | Gamsjaeger S, Srivastava AK, Wergedal JE, et al. Altered bone material properties in HLA-B27 rats include reduced mineral to matrix ratio and altered collagen cross-links[J]. J Bone Miner Res, 2014, 29(11): 2382-2391. doi:10.1002/jbmr.2268pmid:24771481 |
| [20] | Kim SC, Paik JM, Liu J, et al. Gout and the risk of non-vertebral fracture[J]. J Bone Miner Res, 2017, 32(2): 230-236. doi:10.1002/jbmr.2978URL |
| [21] | Ceccarelli F, Perricone C, Colasanti T, et al. Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus[J]. Arthritis Res Ther, 2018, 20(1): 126. doi:10.1186/s13075-018-1622-zpmid:29898764 |
| [22] | Cramarossa G, Urowitz MB, Su J, et al. Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus[J]. Lupus, 2017, 26(4):365-372. doi:10.1177/0961203316664597pmid:27522094 |
| [23] | Ruaro B, Casabella A, Paolino S, et al. Dickkopf-1 (Dkk-1) serum levels in systemic sclerosis and rheumatoid arthritis patients: correlation with the Trabecular Bone Score(TBS)[J]. Clinical Rheumatol, 2018, 37(11):3057-3062. doi:10.1007/s10067-018-4322-9URL |
| [24] | Hu Z, Zhu S, Zhang B. Impaired bone health in patients with primary Sjogren’s syndrome[EB/J]. Arthritis Rheumatol, 2016. https://acrabstracts.org/abstract/impaired-bone-health-in-patients-with-primary-sjogrens-syndrome/. |
| [25] | Englund M, Merkel PA, Tomasson G, et al. Comorbidities in patients with antineutrophil cytoplasmic antibody-associated vasculitis versus the general population[J]. J Rheumatol, 2016, 43(8): 1553-1558. doi:10.3899/jrheum.151151pmid:27252425 |
| [26] | Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials[J]. Ann Rheum Dis, 2015, 74(1): 177-184. doi:10.1136/annrheumdis-2013-203927URL |
| [27] | Raterman HG, Lems WF. Pharmacological management of osteoporosis in rheumatoid arthritis patients: a review of the literature and practical guide[J]. Drugs Aging, 2019, 36(12): 1061-1072. doi:10.1007/s40266-019-00714-4pmid:31541358 |
| [28] | Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis[J]. Cochrane Database Syst Rev, 2015(4): CD005468. |
| [29] | Chen YM, Chen HH, Huang WN, et al. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis[J]. PLoS One, 2017, 12(11): e0188454. |
| [30] | Dubrovsky AM, Lim MJ, Lane NE. Osteoporosis in rheumatic diseases: anti-rheumatic drugs and the skeleton[J]. Calcif Tissue Int, 2018, 102(5): 607-618. doi:10.1007/s00223-018-0401-9URL |
| [31] | Chen XD, Xiao P, Lei SF, et al. Gene expression profiling in monocytes and SNP association suggest the importance of the STAT1 gene for osteoporosis in both Chinese and Caucasians[J]. J Bone Miner Res, 2010, 25(2): 339-355. doi:10.1359/jbmr.090724URL |
| [32] | Zhou H, Newnum AB, Martin JR, et al. Osteoblast/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species[J]. Bone, 2011, 49(3): 404-411. doi:10.1016/j.bone.2011.04.020URL |
| [33] | Solomon DH, Kay J, Duryea J, et al. Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial[J]. Arthritis Rheumatol, 2017, 69(9): 1741-1750. doi:10.1002/art.40156URL |
| [34] | Yue J, Griffith JF, Xiao F, et al. Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study[J]. Arthritis Care Res (Hoboken), 2017, 69(8):1156-1163. doi:10.1002/acr.23133URL |
| [35] | Ostrovsky V, Malnick S, Ish-Shalom S, et al. Denosumab-induced immune hepatitis[J]. Biomedicines, 2021, 9(1): 76. doi:10.3390/biomedicines9010076URL |
| [1] | 杜艳萍, 程群.骨质疏松症使用甲状旁腺激素类似物和双膦酸盐序贯治疗的机制及策略[J]. 诊断学理论与实践, 2020, 19(03): 219-224. |
| [2] | 肖超, 常春康,.骨髓瘤骨病的病理机制进展与治疗[J]. 诊断学理论与实践, 2015, 14(04): 375-380. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
